期刊
PHARMACEUTICS
卷 13, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics13050683
关键词
acute lung injury; acute respiratory distress syndrome; inflammation; LPS; resveratrol; nanocarriers
资金
- Rede Rio de Inovacao em Nanossistemas para a SaudeNanoSAUDE/FAPERJ [E-26/010.000983/2019]
The study demonstrated that nanoencapsulated resveratrol can increase its bioavailability, enhancing therapeutic effects in an LPS-induced lung injury model by improving antioxidant and anti-inflammatory effects, reducing pulmonary inflammation, and improving lung function.
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are inflammatory and oxidative imbalance lung conditions with no successful pharmacological therapy and a high mortality rate. Resveratrol (RSV) is a plant-derived stilbene that presents anti-inflammatory and antioxidant effects. However, its therapeutic application remains limited due to its poor bioavailability, which can be solved by the use of nanocarriers. Previously, we demonstrated that nanoencapsulated RSV (RSV-LNC) pre-treatment, performed 4 h before lipopolysaccharide (LPS) stimulation in mice, increased its anti-inflammatory properties. In this study, we evaluated the anti-inflammatory and antioxidant effects, and lung distribution of RSV-LNCs administered therapeutically (6 h post LPS exposure) in a lung injury mouse model. The results showed that RSV-LNCs posttreatment improved lung function and diminished pulmonary inflammation. Moreover, RSV-LNC treatment enhanced the antioxidant catalase level together with a decrease in the oxidative biomarker in mouse lungs, which was accompanied by an increase in pulmonary Nrf2 antioxidant expression. Finally, the presence of RSV in lung tissue was significantly detected when mice received RSV-LNCs but not when they received RSV in its free form. Together, our results confirm that RSV nanoencapsulation promotes an increase in RSV bioavailability, enhancing its therapeutic effects in an LPS-induced lung injury model.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据